98%
921
2 minutes
20
Rationale: Chronic lung disease is common in adolescents with perinatally acquired HIV (PHIV). HRCT provides delineation of chronic changes. Our aim was to investigate the association of HRCT findings with lung function in PHIV.
Methods: Prospective evaluation of participants in the Cape Town Adolescent Antiretroviral Cohort (CTAAC); perinatally infected YLHIV established on cART. HRCT was performed in participants with abnormal lung function (forced expiratory volume in 1 s [FEV1] of < 80% predicted and/or lung diffusion capacity [DLCO] < 80% predicted) or for clinical symptoms. Spirometry (pre and post bronchodilator) and DLCO (diffusion capacity) was correlated with HRCT findings.
Results: There were 100 participants, (median [IQR] age 13.8 (IQR = 12.8, 15.1) years) 46% males. Median age at HIV diagnosis of 3.7 years (IQR = 1.6, 6.9). Median cART duration was 9.9 years (IQR = 7.1;11.5). CD4 count was > 500 cells/mm in 83%. HIV-viral load was < 50 copies/mL in 72%. All participants had abnormal HRCT findings; mosaic attenuation (73/100) was most prevalent. Bronchiectasis occurred in 39/100. Correlation was found between the extent of mosaic attenuation and reduced FEV (r = -0.5; p < 0.001), consistent with airflow obstruction. Extent of bronchiectasis and reduced FEV (r = -0.5; p < 0.001) were strongly correlated. No correlation found between extent of mosaic attenuation or bronchiectasis and DLCO. Most (90%) patients with mosaic attenuation or bronchiectasis were not bronchodilator responsive.
Conclusion: Mosaic attenuation and bronchiectasis were the most common abnormality on HRCT. The extent of these changes strongly correlated with reduced FEV. The extent of disease on HRCT is useful for inferring functional airway obstruction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340574 | PMC |
http://dx.doi.org/10.1002/ppul.71234 | DOI Listing |
Tuberc Respir Dis (Seoul)
September 2025
Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Seoul, Korea.
Background: Little is known about the transition to frequent exacerbators in stabilized patients with chronic obstructive pulmonary disease (COPD).
Methods: This study utilized data obtained from the Korean COPD subgroup study cohort (KOCOSS), including 511 patients with infrequent exacerbations. The outcome for these groups was progression to frequent exacerbators.
Ann Allergy Asthma Immunol
September 2025
Department of Pneumology, University Hospital Saint-Luc, Brussels, Belgium; Pole Pneumology, ENT, and Dermatology - LUNS, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium.
Background: Different biologics available as add-on treatment for severe asthma (SA) showed modest benefits on lung function parameters but head-to-head comparisons are lacking.
Objective: This study aims to compare the effects of four biologics on lung function parameters (including small airways) at 6 and 12 months of treatment in patients with SA.
Methods: An observational multicenter study was conducted on adults patients with SA naïve to biologics treated by benralizumab, dupilumab, mepolizumab and omalizumab with lung function assessment by spirometry and gas dilution method at baseline (T0), after 6 (T6) and 12 months (T12) of treatment.
Transpl Immunol
September 2025
Intensive Care, Royal Free Hospital, Hampstead, London, United Kingdom.
Background: Inflammatory injury in organ donors, particularly after brain death and during ischemia-reperfusion, contributes to graft dysfunction, rejection, and reduced survival. Statins, beyond their lipid-lowering role, exert pleiotropic anti-inflammatory and immunomodulatory effects, including IL-6 suppression, NF-κB inhibition, immune cell modulation, and potential alteration of exosome secretion.
Methods: Building upon this background, this narrative review synthesises preclinical and clinical evidence on pre-donation statin therapy in solid organ transplantation.
Cell Signal
September 2025
Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Respiratory Immunology research center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality. 2.48 million new cases were reported globally in 2022, driven by rising adenocarcinoma rates linked to environmental factors such as air pollution.
View Article and Find Full Text PDFAm J Respir Crit Care Med
September 2025
Temple University Hospital, Pulm & Crit Care Medicine, Philadelphia, Pennsylvania, United States.
Rationale: AIRFLOW-3 was a 1:1 randomized, double blind, sham controlled trial of the d'Nerva Targeted Lung Denervation (TLD) System in patients with COPD.
Objective: Evaluate the impact of TLD on COPD exacerbations compared to optimal medical treatment.
Methods: AIRFLOW-3 patients were symptomatic (CAT ≥10) with moderate to very severe airflow obstruction (25% ≤ FEV ≤ 80% predicted) and GOLD E status (≥2 moderate or ≥1 severe exacerbation over prior 12 months).